Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
  • Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis.

Thumbnail
View/Open
Supporting information (63.31Kb)
Date
2017-09
ICR Author
Braconi, Chiara
Marsden,
Author
Ghidini, M
Tomasello, G
Botticelli, A
Barni, S
Zabbialini, G
Seghezzi, S
Passalacqua, R
Braconi, C
Petrelli, F
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Introduction The use of adjuvant treatment (AT) in resected biliary tract cancers (BTC) is still controversial. No efficacy comparison has been performed between chemotherapy (CT) and chemoradiotherapy (CTRT). A systematic review of the available evidence regarding adjuvant chemotherapy (AC) in resected BTC was performed.Methods PubMed, EMBASE, Web of Science, SCOPUS and The Cochrane Library databases were searched for relevant articles published. Only studies including at least 50 patients affected by tumors of gallbladder, intrahepatic, perihilar, and distal bile ducts were considered. Data were pooled using a random-effects model. The primary endpoint of the study was overall survival (OS).Results Thirty studies were analyzed with a total of 22,499 patients, 3967 of whom received AC. Eleven cohorts included Western patients and 19 were Asiatic. Surgeries were classified as R0 with negative margins, R1 with positive microscopic and R2 with positive macroscopic margins. Weighted mean OS difference among experimental (AC) and control arm was 4.3 months (95% CI 0.88-7.79, P = 0.014). AC reduced the risk of death by 41% (Hazard ratio [HR] = 0.59, 95% CI 0.49-0.71; P < 0.001).Conclusions AC administration gives an OS benefit in resected BTC. The results of prospective randomized studies are awaited in order to define the standard AT in BTC.
URI
https://repository.icr.ac.uk/handle/internal/1149
DOI
https://doi.org/10.1016/j.hpb.2017.05.010
Collections
  • Cancer Therapeutics
Subject
Humans
Biliary Tract Neoplasms
Antineoplastic Agents
Treatment Outcome
Chemotherapy, Adjuvant
Biliary Tract Surgical Procedures
Risk Factors
Chi-Square Distribution
Survival Analysis
Time Factors
Research team
Signal Transduction & Molecular Pharmacology
Language
eng
Date accepted
2017-05-20
License start date
2017-09
Citation
HPB : the official journal of the International Hepato Pancreato Biliary Association, 2017, 19 (9), pp. 741 - 748

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.